Lack of Human Data – Current research relies primarily on animal models (e.g., Gunn rats), which may not fully replicate the complexities of kernicterus in human brains.
First-of-its-Kind Opportunity – Blue’s donation, along with Jos’s, represents the first human samples available for long-term kernicterus research, enabling direct study of bilirubin-induced brain damage.
Verification of Findings – Human tissue is critical to confirm or challenge assumptions from animal studies, ensuring the accuracy of research conclusions.
Understanding Long-Term Impact – Existing studies focus on infant cases; research on adult brains with kernicterus will provide insight into lifelong neurodegenerative effects.
Targeting the Affected Cells – Studying human brain tissue allows researchers to pinpoint which brain cells are most vulnerable, leading to a better understanding of kernicterus pathology.
Potential for Neuroprotection & Treatment – Identifying how kernicterus affects brain cells over time could pave the way for future therapies, interventions, and protective strategies.
Exposing the Reality – Denial within the medical community has led to underreporting, misclassification, and dismissal of kernicterus cases. Human brain studies provide undeniable proof of its existence and impact.
Building Infrastructure for Future Research – Just as organ donation required systems to make it accessible, human brain research on kernicterus needs sustainable infrastructure to ensure continued study.
Driving Policy & Prevention – Concrete scientific evidence from human brains can push for stronger medical guidelines, improved newborn jaundice management, and policy changes to prevent future cases.
Families Deserve Answers – Those affected by kernicterus have never had a clear explanation of its full neurological effects. Research can provide clarity, validation, and hope for those living with kernicterus and their families.
